A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

Breast Cancer Research and Treatment

Volumn 165, Issue 2, 2017, Pages 375-382

  Goldstein, Lori J ^a   Zhao, Fengmin ^b   Wang, Molin ^b   Swaby, Ramona F ^a,c   Sparano, Joseph A ^d   Meropol, Neal J ^a,e   Bhalla, Kapil N ^f,g   Pellegrino, Christine M ^d   Katherine Alpaugh, R ^a   Falkson, Carla I ^h   Klein, Paula ^i,j   Sledge, George W ^k,l  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Merck Pharmaceuticals   (United States)

^d West Chester Medical Center   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g AUGUSTA UNIVERSITY   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ BETH ISRAEL MEDICAL CENTER   (United States)

^j Saint Vincents Comprehensive Cancer Center   (United States)

^k STANFORD UNIVERSITY   (United States)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anticancer therapy; Histone deacetylase; Resistance; Toxicity; Tumor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; TRASTUZUMAB; VORINOSTAT; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXAMIC ACID; TUMOR MARKER;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LEUKOCYTE COUNT; LUNG INFILTRATE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THROMBOCYTE COUNT; TIME TO TREATMENT; BREAST TUMOR; CLINICAL TRIAL; DISEASE EXACERBATION; GENE AMPLIFICATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETREATMENT; THORAX WALL; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GENE AMPLIFICATION; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT COMPLIANCE; RECEPTOR, ERBB-2; RETREATMENT; THORACIC WALL; TIME FACTORS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 85020517595     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-017-4310-9     Document Type: Article

References (31)

1. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188–193. doi:10.1038/43710
2. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428. doi:10.1038/nrg816
3. Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343–2350. doi:10.2174/0929867033456657
4. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292–2300
5. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963–970
6. Kitagaki J, Shi G, Miyauchi S, Murakami S, Yang Y (2015) Cyclic depsipeptides as potential cancer therapeutics. Anticancer Drugs 26:259–271. doi:10.1097/CAD.0000000000000183
7. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865–2868. doi:10.1182/blood.V98.9.2865
8. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202. doi:10.1038/35106079
9. Kelly WK, O’Connor OA, Marks PA (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Inv Drug 11:1695–1713. doi:10.1517/13543784.11.12.1695
10. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39. doi:10.1182/blood-2006-06-025999
11. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14:7138–7142. doi:10.1158/1078-0432.CCR-08-0122
12. Winer E, Morrow M, Osborne CK (2000) Malignant tumors of the breast. In: Devita JVT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott-Raven Publishers, Philadelphia, pp 1651–1716
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER2/neu proto-oncogene in human-breast and ovarian-cancer. Science 244:707–712. doi:10.1126/science.2470152
14. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167. doi:10.1093/emboj/19.13.3159
15. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726
16. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. doi:10.1056/NEJM200103153441101
17. Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707–717
18. Lu YH, Zi XL, Zhao YH, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer I 93:1852–1857. doi:10.1093/jnci/93.24.1852
19. Kurokawa H, Arteaga CL (2003) ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 9:511S–515S
20. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer I 92:1210–1216. doi:10.1093/jnci/92.15.1210
21. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21(WAF1) expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014–10019. doi:10.1073/pnas.180316197
22. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates HER2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971–984
23. Huang LL, Pardee AB (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849–866
24. Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213–217
25. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427–436. doi:10.1038/sj.onc.1205108
26. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumor biology—Herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280. doi:10.1038/416279b
27. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10
28. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JA (2012) Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat 132:1063–1072. doi:10.1007/s10549-011-1928-x
29. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104:1828–1835. doi:10.1038/bjc.2011.156
30. Huang X, Wang S, Lee CK, Yang X, Liu B (2011) HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett 307:72–79. doi:10.1016/j.canlet.2011.03.019
31. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31:2128–2135. doi:10.1200/JCO.2012.43.7251